Editorial
Allogeneic anti-CD19 CAR T cells: new perspectives in the treatment of B-cell malignancies that progress after allogeneic stem cell transplantation?
Abstract
Allogeneic stem cell transplantation (ASCT) remains the ultimate curative option for numerous lymphoid malignancies, especially acute lymphoblastic leukemia (ALL). When relapse occurred after ASCT, prognosis is dismal especially in ALL and therapeutic options are limited (1).
Donor lymphocyte infusions (DLIs) of unmanipulated allogeneic lymphocytes from the transplant donor are then commonly used.
Donor lymphocyte infusions (DLIs) of unmanipulated allogeneic lymphocytes from the transplant donor are then commonly used.
